KORA SAÚDE PARTICIPAÇÕES S.A. Financials Kora Saúde Participações S.A.
Equities
KRSA3
BRKRSAACNOR0
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.86 BRL | +14.67% |
|
+13.16% | -33.85% |
| Feb. 28 | Transcript : Kora Saúde Participações S.A., Q4 2023 Earnings Call, Feb 28, 2024 | |
| Feb. 27 | Kora Saúde Participações S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 3,972 | 602.3 | 999 | 660.9 | - | - |
| Enterprise Value (EV) 1 | 5,262 | 2,241 | 999 | 2,998 | 2,826 | 2,773 |
| P/E ratio | -46.9 x | -5.59 x | -6 x | -14.6 x | 15 x | 7.5 x |
| Yield | - | - | - | 1.16% | 1.16% | 3.49% |
| Capitalization / Revenue | 3.15 x | 0.29 x | 0.44 x | 0.27 x | 0.26 x | 0.25 x |
| EV / Revenue | 4.17 x | 1.09 x | 0.44 x | 1.24 x | 1.12 x | 1.04 x |
| EV / EBITDA | 17 x | 5.68 x | 1.95 x | 5.91 x | 5.36 x | 4.75 x |
| EV / FCF | -62.9 x | 15 x | - | 8.15 x | 12.1 x | 8.61 x |
| FCF Yield | -1.59% | 6.65% | - | 12.3% | 8.25% | 11.6% |
| Price to Book | 3.18 x | 0.49 x | - | 0.57 x | - | - |
| Nbr of stocks (in thousands) | 765,255 | 772,231 | 768,481 | 768,481 | - | - |
| Reference price 2 | 5.190 | 0.7800 | 1.300 | 0.8600 | 0.8600 | 0.8600 |
| Announcement Date | 3/30/22 | 3/28/23 | 2/27/24 | - | - | - |
1BRL in Million2BRL
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 612.3 | 1,262 | 2,047 | 2,260 | 2,421 | 2,531 | 2,672 |
| EBITDA 1 | - | 309.9 | 394.6 | 511.5 | 507 | 526.9 | 583.7 |
| EBIT 1 | - | 236.6 | 270.5 | 343.9 | 363.3 | 390.7 | 434.3 |
| Operating Margin | - | 18.75% | 13.22% | 15.22% | 15.01% | 15.44% | 16.25% |
| Earnings before Tax (EBT) 1 | - | 2.834 | -89.72 | -134 | -48.16 | 42.66 | 102 |
| Net income 1 | - | -54.96 | -94.47 | -158.1 | -51.6 | 23.27 | 63.67 |
| Net margin | - | -4.36% | -4.62% | -7% | -2.13% | 0.92% | 2.38% |
| EPS 2 | 0.8800 | -0.1106 | -0.1396 | -0.2168 | -0.0589 | 0.0573 | 0.1146 |
| Free Cash Flow 1 | - | -83.72 | 149 | - | 368 | 233 | 322 |
| FCF margin | - | -6.63% | 7.28% | - | 15.2% | 9.21% | 12.05% |
| FCF Conversion (EBITDA) | - | - | 37.76% | - | 72.59% | 44.22% | 55.17% |
| FCF Conversion (Net income) | - | - | - | - | - | 1,001.25% | 505.72% |
| Dividend per Share 2 | - | - | - | - | 0.0100 | 0.0100 | 0.0300 |
| Announcement Date | 4/7/21 | 3/30/22 | 3/28/23 | 2/27/24 | - | - | - |
1BRL in Million2BRL
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 324.5 | 414 | 478.7 | 518.8 | 511.2 | 538 | 553 | 565 | 577 | 564.7 | 570 | - | - | - |
| EBITDA 1 | 78.4 | 83.9 | 111.5 | 118 | 110.8 | 104.3 | 112.1 | 130.3 | 131.8 | 137.4 | 125 | - | - | - |
| EBIT | 60.2 | 53.8 | 88.5 | 105 | 51.7 | 57.7 | 74 | 92.76 | 87.92 | 89.3 | - | - | - | - |
| Operating Margin | 18.55% | 12.99% | 18.49% | 20.24% | 10.11% | 10.73% | 13.38% | 16.42% | 15.24% | 15.81% | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | -53.4 | -67.08 | - | - | - | - | - | - | - | - |
| Net income | -14.72 | -74.67 | 14.15 | -2.787 | -55.47 | -59.02 | -48.04 | - | -41.78 | -19.56 | - | - | - | - |
| Net margin | -4.54% | -18.03% | 2.96% | -0.54% | -10.85% | -10.97% | -8.69% | - | -7.24% | -3.46% | - | - | - | - |
| EPS 2 | -0.0300 | -0.1506 | 0.0180 | -0.003700 | -0.0720 | -0.0824 | -0.0656 | -0.0679 | -0.0585 | -0.0245 | -0.009250 | 0.007330 | -0.000780 | 0.004980 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/12/21 | 3/30/22 | 5/13/22 | 8/11/22 | 11/11/22 | 3/28/23 | 5/16/23 | 8/7/23 | 11/6/23 | 2/27/24 | - | - | - | - |
1BRL in Million2BRL
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 1,290 | 1,639 | - | 2,337 | 2,165 | 2,112 |
| Net Cash position 1 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 4.164 x | 4.153 x | - | 4.609 x | 4.109 x | 3.618 x |
| Free Cash Flow 1 | - | -83.7 | 149 | - | 368 | 233 | 322 |
| ROE (net income / shareholders' equity) | - | 7.09% | -9.01% | - | 0.58% | 3.89% | 6.53% |
| ROA (Net income/ Total Assets) | - | 2.01% | -2.18% | - | 0.04% | 0.9% | 1.61% |
| Assets 1 | - | -2,733 | 4,333 | - | -135,787 | 2,583 | 3,955 |
| Book Value Per Share 2 | - | 1.630 | 1.580 | - | 1.500 | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | 99.1 | 132 | 91.2 | 73 | 84.5 | 89 |
| Capex / Sales | - | 7.85% | 6.47% | 4.04% | 3.02% | 3.34% | 3.33% |
| Announcement Date | 4/7/21 | 3/30/22 | 3/28/23 | 2/27/24 | - | - | - |
1BRL in Million2BRL
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
0.86
BRL
Average target price
1.55
BRL
Spread / Average Target
+80.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -33.85% | 129M | |
| -20.16% | 16.21B | |
| +4.50% | 12.44B | |
| +3.98% | 11.58B | |
| +9.72% | 10.79B | |
| +23.61% | 8.26B | |
| -2.19% | 7.68B | |
| +20.75% | 7.2B | |
| +4.49% | 6.67B | |
| +50.89% | 4.66B |
- Stock Market
- Equities
- KRSA3 Stock
- Financials Kora Saúde Participações S.A.
